Abbott Laboratories stock: Product pipeline gains two updates

Abbott Laboratories announced two product developments on Tuesday, November 10, spanning consumer diagnostics and cardiac devices. The updates add regulatory and product milestones as investors assess the healthcare group's pipeline.

New developments across two businesses

Abbott introduced a new Panbio COVID-19/Flu A&B self-test for Canadian families during the respiratory illness season. The product is positioned to support at-home testing for both COVID-19 and influenza A and B.

The company also announced FDA approval and CE marking for an implantable cardioverter-defibrillator lead designed to work with the heart's natural electrical system. The milestone strengthens Abbott's presence in cardiac rhythm management, where product approvals can shape the pace of portfolio expansion.

The announcements were listed in Abbott's MediaRoom on November 10.

What investors should watch next

The self-test addresses seasonal respiratory diagnostics, while the cardiac lead targets a more specialized medical-device market. Together, the releases show Abbott advancing products with different regulatory and commercial profiles rather than relying on a single pipeline catalyst.

Abbott Laboratories stock traded at 98.48 euros on Lang & Schwarz at 10:27 CET on Saturday, November 14, 2026.

US healthcare shares remain sensitive to regulatory decisions and product launches. Current market reports are available through Current market reports.

More news and analyses are available on Abbott Laboratories stock.